ER expression in HER2+ BC implies a distinct biology compared with that of HER2+, ER– BC: patients diagnosed with HER2+, ER+ BC have tumors that are less proliferative, have lower HER2 gene amplification, and thereby are more frequently of the luminal subtype [49, 72]. Here, ERBB2 is linked to breast cancer.